Gain Therapeutics (NASDAQ:GANX) Announces Earnings Results

Gain Therapeutics (NASDAQ:GANX) issued its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.07, Zacks reports.

Gain Therapeutics Price Performance

Shares of GANX stock traded down $0.07 during trading hours on Friday, reaching $2.01. The stock had a trading volume of 82,915 shares, compared to its average volume of 279,742. The stock’s fifty day simple moving average is $2.23 and its 200 day simple moving average is $2.05. The firm has a market capitalization of $53.18 million, a PE ratio of -1.82 and a beta of 0.14. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $4.04. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, March 17th. Roth Mkm reiterated a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Scotiabank assumed coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Chardan Capital reissued a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a report on Friday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.